Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis - Overview
Bacterial Vaginosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis - Companies Involved in Therapeutics Development
Dare Bioscience Inc
Evofem Biosciences Inc
Melinta Therapeutics Inc
Osel Inc
Pharmiva AB
Starpharma Holdings Ltd
Bacterial Vaginosis - Drug Profiles
Amphora - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clindamycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metronidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radezolid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
subtilosin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNP-2198 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacterial Vaginosis - Dormant Projects
Bacterial Vaginosis - Discontinued Products
Bacterial Vaginosis - Product Development Milestones
Featured News & Press Releases
Sep 21, 2018: New Data on Patient Acceptability and Genitouriry Effects of Evofem Biosciences’ Amphora and its Role as a Multipurpose Vagil pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine Annual Congress
Jul 09, 2018: VivaGel BV NDA advances to next stage of FDA review
Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel BV
Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vagil Microbiomes
Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US
Oct 25, 2017: VivaGel BV granted marketing approval in Australia
Aug 07, 2017: Successful VivaGel Phase 3 results and NDA planned for rBV
Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregncy
Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation
Jun 29, 2017: AMPHORA (L-lactic Acid, citric acid, and potassium bitartrate) Receives "Qualified Infectious Disease Product" (QIDP) Desigtion from the FDA
Mar 30, 2017: VivaGel BV phase 3 trials for prevention of BV completed
Jan 12, 2017: VivaGel BV granted QIDP and Fast Track desigtion by US FDA
Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program
Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vagil pH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Bacterial Vaginosis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019


List of Tables


Number of Products under Development for Bacterial Vaginosis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Bacterial Vaginosis - Pipeline by Dare Bioscience Inc, H1 2019
Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, H1 2019
Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, H1 2019
Bacterial Vaginosis - Pipeline by Osel Inc, H1 2019
Bacterial Vaginosis - Pipeline by Pharmiva AB, H1 2019
Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H1 2019
Bacterial Vaginosis - Dormant Projects, H1 2019
Bacterial Vaginosis - Discontinued Products, H1 2019